EMA starts safety-related review of obesity drug

The EMA has started a review of drugs containing substance amfepramone, which is typically used to dampen appetites as a treatment for obesity.
Photo: Rob Acket/EMA
Photo: Rob Acket/EMA
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN

Following a request from the Romanian medicines agency, the European Medicines Agency (EMA) has started reviewing the substance amfepramone, which is an ingredient in several drugs used for treating obesity.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading